Kit for detecting expression index of mRNA (messager Ribose Nucleic Acid) of WT1 (Wilms Tumor 1) gene

Abstract

The invention relates to a kit for detecting an expression index of mRNA (messager Ribose Nucleic Acid) of a WT1 (Wilms Tumor 1) gene, and belongs to the field of biotechnology. The kit comprises detection primers, a fluorescent probe, a cDNA (complementary Deoxyribose Nucleic Acid) first strand synthesis reagent, a fluorescent quantitative PCR (Polymerase Chain Reaction) mixed solution, negative reference and positive reference, wherein the detection primers and the fluorescent probe comprise a WT1 gene primer, an internal reference gene ABL primer and a Taqman fluorescent probe. The WT1 gene is related with hematopoietic tumor incidence, is of over-expression in about 80% of patients with newly diagnosed acute myelocytic leukemia and acute lymphocytic leukemia, is recognized as a leukemia marker gene, and can serve as an independent minimal residue disease monitoring and prognosis prompting index. The level of the mRNA of the WT1 gene is detected by adopting a fluorescent quantitative PCR technology with higher sensitivity and specificity, and both the specificity and the sensitivity of a detection result are remarkably improved. The kit provides a brand-new quick, simple and convenient gene diagnosis technology for prognosing the acute myelocytic leukemia and the acute lymphocytic leukemia and confirming chemotherapy regimens.

Description

technical field

[0001] The invention relates to fluorescence quantitative PCR technology in the field of biotechnology, in particular to a kit for detecting the expression level of WT1 gene mRNA. Background technique

[0002] Acute myeloid leukemia (AML) is a clinically heterogeneous malignant clonal disease and the most common type of acute leukemia. There are more than 11,900 new cases in the United States every year. Most AML patients are middle-aged and elderly people. . About half of adult AML patients lack chromosomal aberrations, and although these patients have a longer prognosis, only 40% survive long-term. Minimal residual disease (Minimal Residual Disease, MRD) is the state of residual leukemia cells in the body after ALL patients have been treated and achieved clinical complete remission according to the curative effect standard determined above. MRD is an important independent prognostic indicator for ALL. It has been confirmed that MRD in children is of grea...

Images